Amgen wins appeals court ruling in patent dispute over psoriasis drug Otezla
hapabapa


A U.S. appeals court sided with Amgen (NASDAQ:AMGN) on Wednesday, dealing a setback to Novartis (NYSE:NVS) and Zydus Pharmaceuticals in a patent litigation related to their bid to launch generic versions of the company's blockbuster psoriasis drug Otezla.
Blocking Otezla generics until 2028, the U.S. Court of Appeals for the Federal Circuit upheld a lower court ruling that determined Amgen's patents were valid and proposed generics from Zydus and Novartis' (OTCPK:NVSEF) Sandoz would infringe them.

However, the court affirmed a ruling to invalidate one of Amgen's (AMGN) patents that, according to Sandoz, would have blocked generic versions of Otezla until 2034.
Noting that the verdict allows the market entry of Otezla copycats in 2028 rather than 2034, Sandoz welcomed the decision, Reuters reported citing a company spokesperson.
Read: Seeking Alpha contributor William Meyers issued an in-depth view on Amgen (AMG) after the company acquired the oral treatment from Bristol Myers' (BMY) unit Celgene in November 2019.